Results 151 to 160 of about 5,782,005 (384)

Inhibition of FOXM1 Synergizes with BH3 Mimetics Venetoclax and Sonrotoclax in Killing Multiple Myeloma Cells through Repressing MYC Pathway

Advanced Science, EarlyView.
Relapsed and refractory multiple myeloma remains a major clinical challenge. This study shows that FOXM1 contributes to resistance against BH3 mimetics in multiple myeloma cells. The FOXM1 inhibitor NB73 enhances the effectiveness of BH3 mimetics by reducing FOXM1 expression and suppressing the MYC pathway.
Zhi Wen, Yidan Wang, Kathryn C. Fox, Adam M. Bissonnette, Luke F. Moat, Terrie E. Kitchner, Kelsey Springstroh, Sung Hoon Kim, Dagna S. Sheerar, Patcharon Tanawattanacharoen, Chady A. Leon, Seth O. Fagbemi, John A. Katzenellenbogen, Scott J. Hebbring, Benita S. Katzenellenbogen, Siegfried Janz, Adedayo A. Onitilo   +16 more
wiley   +1 more source

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

Journal of Hematology & Oncology, 2018
Even with recent advances in therapy regimen, multiple myeloma patients commonly develop drug resistance and relapse. The relevance of targeting the PD-1/PD-L1 axis has been demonstrated in pre-clinical models.
Rosemarie Tremblay-LeMay, Nasrin Rastgoo, Hong Chang   +2 more
doaj   +1 more source

Harnessing the Biological Responses Induced by Nanomaterials for Enhanced Cancer Therapy

Aggregate, EarlyView.
Nanomaterial (NM)‐induced toxicity can be strategically repurposed for cancer therapy. This review summarizes the mechanism by which NMs selectively activate specific cellular processes to regulate cell fate independently. We also discussed how NMs‐induced biological responses can be leveraged as therapeutic strategies for cancer treatment.
Liting Wang, Hao Fu, Jiangtao Lin, Meng Zhao, Chuanrong Chen, Hongze Liao, Yourong Duan   +6 more
wiley   +1 more source

Bioinformatics Analysis of the Key Genes and Pathways in Multiple Myeloma

International Journal of General Medicine, 2022
Xinge Sheng,1,2,* Shuo Wang,2,* Meijiao Huang,1 Kaiwen Fan,1,2 Jiaqi Wang,1,2 Quanyi Lu1,2 1Department of Hematology, Zhongshan Hospital Xiamen University, Xiamen, People’s Republic of China; 2Clinical Medicine Department, School of Medicine ...
Sheng X, Wang S, Huang M, Fan K, Wang J, Lu Q   +5 more
doaj  

The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1

Journal of Hematology & Oncology, 2010
Background Heat shock protein 90 (HSP90) inhibitors have emerged as a promising class of anti-cancer drugs in both solid and hematologic malignancies.
Li Zihai, Chiosis Gabriela, Bona Robert D, Usmani Saad Z   +3 more
doaj   +1 more source

MULTIPLE MYELOMA. IV. ABNORMAL SERUM COMPONENTS AND BENCE JONES PROTEIN 1 [PDF]

, 1951
R. Wayne Rundles, Gerald R. Cooper, Robert W. Willett   +2 more
openalex   +1 more source

Acute kidney injury on chronic kidney disease: From congestive heart failure to light chain deposition disease and cast nephropathy in multiple myeloma [PDF]

, 2019
Acute on chronic renal failure is a common but notably broad diagnosis. We present a 64-year-old man with a history of diastolic heart failure and chronic kidney disease, admitted for an elevated creatinine.
Cheng, Steven, Lacasse, Alexandre, Nwankwo, Christian, Shaikh, Sana   +3 more
core   +1 more source

Determinants of 15‐Year Progression‐Free Survival in Multiple Myeloma; Real‐World Data From a Single Institution

American Journal of Hematology, EarlyView.
9% of patients with multiple myeloma achieve 15‐year progression‐free survival; Kaplan‐Meier curves for PFS (A) and OS (B). ABSTRACT The therapeutic advances during the last two decades have rendered multiple myeloma a chronic disease and, thus, it is important to identify patient subgroups which may have extremely favorable outcomes and optimize their
Meletios A. Dimopoulos, Ioannis Ntanasis‐Stathopoulos, Despina Fotiou, Foteini Theodorakakou, Eirini Solia, Vasiliki Spiliopoulou, Panagiotis Malandrakis, Erasmia Psimenou, Stavroula Giannouli, Nikolaos Kanellias, Vassilis Koutoulidis, Maria Roussou, Angeliki Andrikopoulou, Magdalini Migkou, Evangelos Eleutherakis‐Papaiakovou, Maria Gavriatopoulou, Evangelos Terpos, Efstathios Kastritis   +17 more
wiley   +1 more source

GRP78-directed immunotherapy in relapsed or refractory multiple myeloma - results from a phase 1 trial with the monoclonal immunoglobulin M antibody PAT-SM6

Haematologica, 2015
The primary objective of this phase 1 study was to evaluate the safety and tolerability of the anti-glucose regulated protein 78 monoclonal immunoglobulin M antibody PAT-SM6 in subjects with relapsed or refractory multiple myeloma.
Leo Rasche, Johannes Duell, Inês C. Castro, Valentina Dubljevic, Manik Chatterjee, Stefan Knop, Frank Hensel, Andreas Rosenwald, Hermann Einsele, Max S. Topp, Stephanie Brändlein   +10 more
doaj   +1 more source

FRACTIONATION OF SERUM PROTEINS IN HYPERPROTEINEMIA, WITH SPECIAL REFERENCE TO MULTIPLE MYELOMA [PDF]

, 1941
Alexander B. Gutman, Dan H. Moore, E. B. Gutman, Virginia McClellan, Elvin A. Kabat   +4 more
openalex   +1 more source